Ethics approval for health preference DCE studies

Patient preference studies invariably require ethics approval. Getting this right from the start saves weeks of delay and protects your study's credibility.

This article explains when ethics approval is required for health preference DCEs, what IRBs and ethics committees look for, and how to prepare a successful application.

Ben White, 07.07.2026

When ethics approval is required

Any research involving identifiable health information - diagnosis, treatment history, symptoms, functional status - typically requires ethics review. Patient preference DCEs that recruit participants with confirmed diagnosis and collect information about their health status and treatment experience almost always require ethics approval.

The requirements vary by jurisdiction. In the US, studies collecting individually identifiable health information are subject to IRB review under 45 CFR 46 (the Common Rule). In the EU, studies involving personal data are subject to GDPR and, if conducted in clinical settings, to the Medical Devices Regulation or drug trial regulations. In the UK, NHS Research Ethics Committee (REC) approval is required for studies involving NHS patients.

What ethics committees look for in DCE studies

Ethics committees reviewing patient preference DCEs focus on three main areas: participant protection (consent, confidentiality, right to withdraw), scientific validity (is the study design capable of producing reliable and meaningful results?), and proportionality (is the burden on participants proportionate to the potential benefits of the research?).

Scientific validity is often overlooked by researchers applying for ethics approval, but many committees now include at least one member with statistical or methodological expertise who will scrutinise the DCE design. A poorly designed study that produces unreliable results is not ethically acceptable even if participant protection is adequate.

Specific DCE-related issues that ethics committees raise include: the cognitive burden of the choice tasks, especially for patient populations who may be fatigued or cognitively impaired; the realism of the scenarios presented; and the management of distressing content (for example, discussing mortality risk or severe side effects).

TLDR Quick links

SurveyEngine health resources

Informed consent article

Open a free account

Preparing a successful ethics application for a DCE study

Step 1: Determine which committee has jurisdiction. Identify whether your study requires IRB review, NHS REC review, or another ethics committee based on where participants are recruited, who is conducting the research, and what data is collected.

Step 2: Prepare the study protocol. Write a clear, detailed protocol describing the study objectives, the DCE design, the recruitment strategy, the data collection procedures, and the data analysis plan. Include a copy of the survey instrument with all attributes, levels, and choice tasks.

Step 3: Prepare the informed consent documentation. Create a participant information sheet and consent form that is appropriate for your target population. For patient populations, this should be written at a reading age of approximately 12 years and reviewed by patient representatives.

Step 4: Address cognitive burden explicitly. Ethics committees will ask about cognitive burden, especially for patient populations. Describe your pilot study plan, how you will monitor completion times, and what steps you will take if the study proves more burdensome than anticipated.

Step 5: Plan for adverse event monitoring. If your study involves asking patients about severe symptoms or distressing health experiences, you need a procedure for monitoring and responding to participant distress. Describe this in the protocol.

Worked example - NHS REC application for oncology study

A patient preference study recruiting lung cancer patients through NHS oncology clinics applies for NHS REC approval. The application includes: study protocol (30 pages), survey instrument including all DCE attributes and levels, PIS and consent form reviewed by a patient representative, pilot study protocol, data management plan compliant with NHS data governance standards, and letters of support from participating clinicians.

The REC raises three queries: (1) cognitive burden for patients receiving active chemotherapy - the protocol is revised to exclude patients with Eastern Cooperative Oncology Group (ECOG) performance status 3 or 4; (2) the realism of the cost attribute (the REC questions whether patients can realistically evaluate out-of-pocket costs); (3) procedures for supporting patients who become distressed when discussing mortality. The protocol is revised to address all three and REC approval is granted.